Kazia Therapeutics Limite... (KZIA)
0.85
-0.00 (-0.17%)
At close: Mar 03, 2025, 12:09 PM
No 1D chart data available
| Bid | 0.85 |
| Market Cap | 2.83M |
| Revenue (ttm) | 3.2M |
| Net Income (ttm) | -37.17M |
| EPS (ttm) | -6.41 |
| PE Ratio (ttm) | -0.13 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.9 |
| Volume | 7,849 |
| Avg. Volume (20D) | 1,978,894 |
| Open | 0.85 |
| Previous Close | 0.85 |
| Day's Range | 0.83 - 0.86 |
| 52-Week Range | 0.78 - 15.80 |
| Beta | 2.11 |
About KZIA
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Thera...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 6, 1999
Employees 9
Stock Exchange NASDAQ
Ticker Symbol KZIA
Analyst Forecast
According to 2 analyst ratings, the average rating for KZIA stock is "Buy." The 12-month stock price forecast is $11.5, which is an increase of 1251.35% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago
+37.68%
Kazia Therapeutics shares are trading higher follo...
Unlock content with
Pro Subscription
2 months ago
-42.9%
Kazia Therapeutics shares are trading lower after the FDA announced the secondary endpoint data on OS from the GBM-AGILE study would not be appropriate for accelerated approval.
